Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences is experiencing robust sales growth, primarily driven by increased demand and market share gains—particularly in its HIV portfolio, with Biktarvy now commanding a 52% market share in the U.S. Gilead's strategic life-cycle management and the expansion of its immunology pipeline further enhance the company's prospects, with revised growth guidance indicating a +5% year-over-year increase despite challenges in the Medicare Part D segment. The company also anticipates an additional $500 million in sales by 2026, supported by a thriving PrEP market and promising early results from collaboration efforts in oncology.

Gilead Sciences is facing significant challenges as evidenced by the decline in key revenue streams, with Trodelvy sales slightly decreasing to $357 million and forecasts predicting a 10% decline in cell therapy revenue for 2025. The company's flagship COVID-19 treatment, Veklury, reported a 60% year-over-year revenue drop to $277 million, well below expectations and contributing to a revised annual revenue guidance decrease from $1.4 billion to $1.0 billion. Additionally, cell therapy sales, experiencing an 11% year-over-year decline to $432 million, indicate increased competitive pressures that are negatively impacting Gilead's financial outlook.